window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 26, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

neuroscience

  • Central Nervous System,Research & Development

    Brain network dynamics may better explain psychiatric symptoms than diagnoses

    Rutgers researchers found that changes in brain network dynamics were [...]

    July 22, 2026
  • Clinical & Regulatory,Research & Development,Therapeutic Areas

    PET imaging reveals widespread synaptic loss in schizophrenia

    Advanced positron emission tomography (PET) imaging has revealed widespread loss [...]

    July 15, 2026
  • Clinical & Regulatory,Digital & Data,Research & Development,Therapeutic Areas

    Two-minute digital test matches clinical benchmarks for Alzheimer’s trial screening

    A two-minute digital cognitive assessment developed by Cumulus Neuroscience performed [...]

    July 15, 2026
  • Biotech & Pharma Business,Central Nervous System

    Alto Neuroscience raises $100M to expand Phase 3 treatment-resistant depression programme

    Alto Neuroscience has raised $100 million through an underwritten registered [...]

    July 15, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development

    Lonza acquires Nona blood-brain barrier technology for CNS therapies

    Lonza has acquired the rights to Nona Biosciences’ transferrin receptor [...]

    July 3, 2026
  • Central Nervous System,Digital & Data,Drug Delivery & Formulation,Drug Discovery & Development,Therapeutic Areas

    Bonito Biosciences partners with DaltonTx on AI-driven RNA delivery research

    Bonito Biosciences has entered a collaboration with DaltonTx to develop [...]

    June 6, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Allucent adds strategy leaders to expand therapeutic expertise

    Allucent has appointed new therapeutic strategy leaders across key disease [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    AI-derived drug candidate reduces fentanyl intake in preclinical opioid study

    A study published in Proceedings of the National Academy of [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Therapeutic Areas

    Rainwater Charitable Foundation announces 2026 Rainwater Prize winners for tauopathy research

    The Rainwater Charitable Foundation (RCF) has announced the recipients of [...]

    May 5, 2026
  • Drug Discovery & Development,Therapeutic Areas

    Successful treatment for ALS could deliver billions in global value

    New research commissioned by Challenge Works and conducted by the [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Natus expands AI-powered EEG analysis across Europe
    Categories: Central Nervous System, Digital & Data, Medical devices
  • Enterome data link CD8 T-cell expansion to progression-free survival in lymphoma
    Categories: Advanced Therapies, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Telix starts Phase 3 trial of radiopharmaceutical therapy for renal cancer
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top